Targeting anti-beta-1-adrenergic receptor antibodies for dilated cardiomyopathy

European Journal of Heart Failure

Volumn 15, Issue 7, 2013, Pages 724-729

  Patel, Priyesh A ^a   Hernandez, Adrian F ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antibodies; Beta 1 adrenergic receptors; Cardiomyopathy; Immunoadsorption; Immunoglobulins

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR ANTIBODY; BIOLOGICAL MARKER; IMMUNOGLOBULIN; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; APHERESIS; CONGESTIVE CARDIOMYOPATHY; DESENSITIZATION; EXCHANGE BLOOD TRANSFUSION; FUNCTIONAL STATUS; HEART HEMODYNAMICS; HUMAN; IMMUNOADSORPTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PLASMAPHERESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; REVIEW;

EID: 84879497304     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hft065     Document Type: Review

References (45)

1. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology InterdisciplinaryWorking Groups; and Council on Epidemiology and Prevention. Circulation 2006;113:1807-1816.
2. Deubner N, Berliner D, Schlipp A, Gelbrich G, Caforio AL, Felix SB, Fu M, Katus H, Angermann CE, Lohse MJ, Ertl G, Stö rk S, Jahns R. Cardiac beta1-adrenoceptor autoantibodies inhuman heart disease: rationale and designof the Etiology, Titre-Course, and Survival (ETiCS) Study. Eur J Heart Fail 2010;12:753-762.
3. Dandel M,Wallukat G, Potapov E, HetzerR. Role of beta(1)-adrenoceptor autoantibodies in the pathogenesis of dilated cardiomyopathy. Immunobiology 2012;217: 511-520.
4. Dandel M, Weng Y, Siniawski H, Potapov E, Drews T, Lehmkuhl HB, Knosalla C, Hetzer R. Prediction of cardiac stability after weaning from left ventricular assist devices in patients with idiopathic dilated cardiomyopathy. Circulation 2008;118: S94-S105.
5. Stork S, BoivinV, Horf R, Hein L, Lohse MJ, Angermann CE, Jahns R. Stimulating autoantibodies directed against the cardiac beta1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J 2006;152:697-704. (Pubitemid 44396891)
6. Jahns R, Boivin V, Siegmund C, Inselmann G, Lohse MJ, Boege F. Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 1999;99:649-654. (Pubitemid 29077363)
7. Iwata M, Yoshikawa T, Baba A, Anzai T, Mitamura H, Ogawa S. Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2001;37:418-424.
8. Limas CJ, Goldenberg IF, Limas C. Autoantibodies against beta-adrenoceptors in human idiopathic dilated cardiomyopathy. Circ Res 1989;64:97-103. (Pubitemid 19028507)
9. Herda LR, Trimpert C, Nauke U, Landsberger M, Hummel A, Beug D, Kieback A, Dorr M, Empen K, Knebel F, Ewert R, Angelow A, Hoffmann W, Felix SB, Staudt A. Effects of immunoadsorption and subsequent immunoglobulinGsubstitution on cardiopulmonary exercise capacity in patients with dilated cardiomyopathy. Am Heart J 2010;159:809-816.
10. Mobini R, Staudt A, Felix SB, Baumann G, Wallukat G, Deinum J, Svensson H, Hjalmarson A, Fu M. Hemodynamic improvement and removal of autoantibodies against beta1-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy. J Autoimmun 2003;20:345-350. (Pubitemid 36677526)
11. Magnusson Y, Marullo S, Hoyer S,Waagstein F, Andersson B, Vahlne A, Guillet JG, Strosberg AD, Hjalmarson A, Hoebeke J. Mapping of a functional autoimmune epitope on the beta 1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1990;86:1658-1663. (Pubitemid 20372617)
12. Wallukat G,Wollenberger A, Morwinski R, Pitschner HF. Anti-beta 1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol 1995;27:397-406.
13. Müller J,Wallukat G,Weng YG, Dandel M, Spiegelsberger S, Semrau S, Brandes K, Theodoridis V, Loebe M, Meyer R, Hetzer R. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation 1997;96: 542-549. (Pubitemid 27329431)
14. Muller J, Wallukat G, Dandel M, Bieda H, Brandes K, Spiegelsberger S, Nissen E, Kunze R, Hetzer R. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000;101:385-391. (Pubitemid 30067394)
15. Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, Ertl G, Lohse MJ. Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 2004;113:1419-1429. (Pubitemid 39071697)
16. Jane-wit D, Altuntas CZ, Johnson JM, Yong S, Wickley PJ, Clark P, Wang Q, Popovic ZB, Penn MS, Damron DS, Perez DM, Tuohy VK. Beta 1-adrenergic receptor autoantibodies mediate dilated cardiomyopathy by agonistically inducing cardiomyocyte apoptosis. Circulation 2007;116:399-410. (Pubitemid 47196545)
17. Wallukat G, Morwinski R, Magnusson Y, Hoebeke J, Wollenberger A. [Autoantibodies against the beta 1-adrenergic receptor in myocarditis and dilated cardiomyopathy: localization of two epitopes]. Z Kardiol 1992;81 Suppl 4:79-83. (Pubitemid 23034630)
18. Freedman NJ, Lefkowitz RJ. Anti-beta(1)-adrenergic receptor antibodies and heart failure: causation, not just correlation. J Clin Invest 2004;113:1379-1382. (Pubitemid 39071690)
19. Patel PA, Tilley DG, Rockman HA. Physiologic and cardiac roles of beta-arrestins. J Mol Cell Cardiol 2009;46:300-308.
20. Pizarro JC, Boulot G, Bentley GA, Gómez KA, Hoebeke J, Hontebeyrie M, Levin MJ, Smulski CR. Crystal structure of the complexmAB17.2 and the C-terminal region of Trypanosoma cruzi P2b protein: implications in cross-reactivity. PLoS Negl Trop Dis 2011;5:e1375.
21. Wallukat G, Muñoz Saravia SG, Haberland A, Bartel S, Araujo R, Valda G, Duchen D, Diaz Ramirez I, Borges AC, Schimke I. Distinct patterns of autoantibodies against G-protein-coupled receptors in Chagas' cardiomyopathy and megacolon. Their potential impact for early risk assessment in asymptomatic Chagas' patients. J Am Coll Cardiol 2010;55:463-468.
22. Levin MJ, Hoebeke J. Cross-talk between anti-beta1-adrenoceptor antibodies in dilated cardiomyopathy and Chagas' heart disease. Autoimmunity 2008;41:429-433.
23. Limas CJ, Iakovis P, Anyfantakis A, Kroupis C, Cokkinos DV. Familial clustering of autoimmune diseases in patients with dilated cardiomyopathy. Am J Cardiol 2004; 93:1189-1191. (Pubitemid 38521060)
24. Schimke I, Muller J, Dandel M, Gremmels HD, Bayer W, Wallukat B, Wallukat G, Hetzer R. Reduced oxidative stress in parallel to improved cardiac performance one year after selective removal of anti-beta 1-adrenoreceptor autoantibodies in patients with idiopathic dilated cardiomyopathy: data of a preliminary study. J Clin Apher 2005;20:137-142. (Pubitemid 43081861)
25. Staudt A, Böhm M, Knebel F, Grosse Y, Bischoff C, Hummel A, Dahm JB, Borges A, Jochmann N, Wernecke KD, Wallukat G, Baumann G, Felix SB. Potential role of autoantibodies belonging to the immunoglobulin g-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation 2002;106:2448-2453. (Pubitemid 35278800)
26. Staudt A, Dörr M, Staudt Y, Böhm M, Probst M, Empen K, Plötz S, Maschke HE, Hummel A, Baumann G, Felix SB. Role of immunoglobulin G3 subclass in dilated cardiomyopathy: results from protein A immunoadsorption. Am Heart J 2005;150: 729-736. (Pubitemid 41396508)
27. Wallukat G, Reinke P, Dörffel WV, Luther HP, Bestvater K, Felix SB, Baumann G. Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption. Int J Cardiol 1996;54:191-195. (Pubitemid 26188306)
28. Dörffel WV, Felix SB, Wallukat G, Brehme S, Bestvater K, Hofmann T, Kleber FX, Baumann G, Reinke P. Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation 1997;95:1994-1997. (Pubitemid 27184263)
29. DörffelWV,Wallukat G,Dörffel Y, Felix SB, Baumann G. Immunoadsorption in idiopathic dilated cardiomyopathy, a 3-year follow-up. Int J Cardiol 2004;97:529-534. (Pubitemid 39550706)
30. Schimke I, Müller J, Priem F, Kruse I, Schon B, Stein J, Kunze R,Wallukat G, Hetzer R. Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption. J Am Coll Cardiol 2001;38:178-183. (Pubitemid 32613847)
31. Felix SB, Staudt A, Dörffel WV, Stangl V, Merkel K, Pohl M, Döcke WD, Morgera S, Neumayer HH, Wernecke KD, Wallukat G, Stangl K, Baumann G. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol 2000;35:1590-1598. (Pubitemid 30307505)
32. Felix SB, Staudt A, Landsberger M, Grosse Y, Stangl V, Spielhagen T, Wallukat G, Wernecke KD, Baumann G, Stangl K. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 2002;39:646-652. (Pubitemid 34158161)
33. Knebel F, Böhm M, Staudt A, Borges AC, Tepper M, Jochmann N, Wernicke KD, Felix S, Baumann G. Reduction of morbidity by immunoadsorption therapy in patients with dilated cardiomyopathy. Int J Cardiol 2004;97:517-520. (Pubitemid 39550704)
34. Yoshikawa T, Baba A, Nagatomo Y. Autoimmune mechanisms underlying dilated cardiomyopathy. Circ J 2009;73:602-607.
35. Dandel M, Wallukat G, Englert A, Lehmkuhl HB, Knosalla C, Hetzer R. Long-term benefits of immunoadsorption in b1-adrenoceptor autoantibody-positive transplant candidates with dilated cardiomyopathy. Eur J Heart Fail 2012;14:1374-1388.
36. Iwata M, Yoshikawa T, Baba A, Anzai T, Nakamura I,Wainai Y, Takahashi T, Ogawa S. Autoimmunity against the second extracellular loop of beta(1)-adrenergic receptors induces beta-adrenergic receptor desensitization and myocardial hypertrophy in vivo. Circ Res 2001;88:578-586. (Pubitemid 32275793)
37. Staudt A, Hummel A, Ruppert J, Dörr M, Trimpert C, Birkenmeier K, Krieg T, Staudt Y, Felix SB. Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study. Am Heart J 2006;152:712.e1-6.
38. Staudt A, StaudtY,HummelA,Empen K,DörrM, Trimpert C, Birkenmeier K,KühlU, Noutsias M, Russ D, Felix SB. Effects of immunoadsorption on the nt-BNP and nt-ANP plasma levels of patients suffering from dilated cardiomyopathy. Ther Apher Dial 2006;10:42-48.
39. Baba A, Akaishi M, Shimada M, Monkawa T, Wakabayashi Y, Takahashi M, Nagatomo Y, Yoshikawa T. Complete elimination of cardiodepressant IgG3 autoantibodies by immunoadsorption in patients with severe heart failure. Circ J 2010; 74:1372-1378.
40. Staudt A, Herda LR, Trimpert C, Lubenow L, Landsberger M, Dörr M, Hummel A, Eckerle LG, Beug D, Muller C, Hoffmann W, Weitmann K, Klingel K, Kandolf R, Kroemer HK, Greinacher A, Felix SB. Fcgamma-receptor IIa polymorphism and the role of immunoadsorption in cardiac dysfunction in patients with dilated cardiomyopathy. Clin Pharmacol Ther 2010;87:452-458.
41. Wallukat G, Müller J, Hetzer R. Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med 2002;347:1806. (Pubitemid 35375628)
42. Port JD, BristowMR. Aptamer therapy for heart failure? Circ Res 2011;109:982-983.
43. Haberland A,Wallukat G, Dahmen C, Kage A, Schimke I. Aptamer neutralization of beta1-adrenoceptor autoantibodies isolated from patients with cardiomyopathies. Circ Res 2011;109:986-992.
44. Wallukat G, Haberland A, Berg S, Schulz A, Freyse EJ, Dahmen C, Kage A, Dandel M, Vetter R, Salzsieder E, Kreutz R, Schimke I. The first aptamer-apheresis column specifically for clearing blood ofb1-receptor autoantibodies. Circ J 2012;76:2449-2455.
45. Munch G, Boivin-Jahns V, Holthoff HP, Adler K, Lappo M, Truol S, Degen H, Steiger N, Lohse MJ, Jahns R, Ungerer M. Administration of the cyclic peptide COR-1 in humans (phase I study): ex vivo measurements of anti-b1-adrenergic receptor antibody neutralization and of immune parameters. Eur J Heart Fail 2012;14: 1230-1239.